In April 2022, Saladax Biomedical, Inc. acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. The IP portfolio includes the 17 patent families and has resulted in 33 US and 296 patents in ex-U.S. countries. With this IP portfolio, Saladax develops tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. With this acquisition, Saladax Biomedical has strengthened its position in the drug testing space.

Saladax Biomedical Acquired Intellectual Property Portfolio of Antipsychotic Drug Testing from Janssen Pharmaceutica NV
In April 2022, Saladax Biomedical, Inc. acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. The IP portfolio includes the 17 patent families and has resulted in 33 US and 296 patents in ex-U.S. countries. With this IP portfolio, Saladax develops tests for chemistry analyzers commonly found…